Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Cardiff Oncology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, JULY 15, 2026 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF) (THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL CANCER THERAPIES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO DEFINITIVE AGREEMENTS FOR THE PURCHASE AND SALE OF AN AGGREGATE OF 8,571,429 SHARES OF ITS COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 8,571,429 SHARES OF ITS COMMON STOCK, AT A PURCHASE PRICE OF $1.05 PER SHARE AND ACCOMPANYING WARRANT IN A REGISTERED DIRECT OFFERING. IN ADDITION, CERTAIN MEMBERS OF THE COMPANY'S OFFICERS AND DIRECTORS ARE PARTICIPATING IN THE OFFERING AND HAVE ENTERED INTO DEFINITIVE AGREEMENTS FOR THE PURCHASE AND SALE OF AN AGGREGATE OF 731,707 SHARES OF THE COMPANY'S COMMON STOCK AND ACCOMPANYING WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 731,707 SHARES OF THE COMPANY'S COMMON STOCK, AT A PURCHASE PRICE OF $1.435 PER SHARE AND ACCOMPANYING WARRANT.

CARDIFF ONCOLOGY ANNOUNCES $10 MILLION REGISTERED DIRECT OFFERING

- THE TRIAL ACHIEVED ITS PRIMARY GOAL OF SELECTING THE EFFICACIOUS AND SAFE DOSE OF ONVANSERTIB + STANDARD-OF-CARE (SOC) REGIMEN FOR THE REGISTRATIONAL PROGRAM -

CARDIFF ONCOLOGY ANNOUNCES PRESENTATION OF POSITIVE RESULTS FROM ITS RANDOMIZED, CONTROLLED PHASE 2 TRIAL OF ONVANSERTIB IN FIRST-LINE RAS-MUTATED MCRC AT THE 2026 ASCO ANNUAL MEETING

SAN DIEGO, JUNE 01, 2026 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PRESENT AND PARTICIPATE IN 1X1 INVESTOR MEETINGS AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE ON JUNE 2-4, 2026.

CARDIFF ONCOLOGY TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

UPDATED PHASE 2 CRDF-004 DATA TO BE PRESENTED DURING ASCO 2026 RAPID ORAL SESSION ON JUNE 2, 2026; INVESTOR WEBCAST SCHEDULED FOR JUNE 3, 2026 AT 8:30 AM ET TO REVIEW THE DATA UPDATED PHASE 2 CRDF-004 DATA TO BE PRESENTED DURING ASCO 2026 RAPID ORAL SESSION ON JUNE 2, 2026; INVESTOR WEBCAST SCHEDULED FOR JUNE 3, 2026 AT 8:30 AM ET TO REVIEW THE DATA

CARDIFF ONCOLOGY ANNOUNCES WEBCAST TO DISCUSS UPDATED PHASE 2 CRDF-004 DATA FOR ONVANSERTIB IN FIRST-LINE RAS-MUTATED MCRC

COMPLETED SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA AND SELECTED ONVANSERTIB DOSE AND CHEMOTHERAPY REGIMEN FOR PLANNED PHASE 3 TRIAL

CARDIFF ONCOLOGY REPORTS FIRST QUARTER 2026 RESULTS AND PROVIDES BUSINESS UPDATE

SAN DIEGO, CALIF., APRIL 28, 2026 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, ANNOUNCED THAT IN CONNECTION WITH DR. AGGARWAL JOINING CARDIFF ONCOLOGY AS CHIEF OPERATING OFFICER, THE COMPANY'S COMPENSATION COMMITTEE APPROVED THE GRANT OF NON-QUALIFIED STOCK OPTIONS TO PURCHASE 400,000 SHARES OF CARDIFF ONCOLOGY COMMON STOCK OUTSIDE OF THE CARDIFF ONCOLOGY 2021 OMNIBUS EQUITY INCENTIVE PLAN.

CARDIFF ONCOLOGY REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

SAN DIEGO, APRIL 27, 2026 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED THAT THE COMPANY WILL HOST A KEY OPINION LEADER (KOL) WEBINAR TO DISCUSS DATA FROM AN INVESTIGATOR-INITIATED TRIAL ON ONVANSERTIB'S SINGLE-AGENT CLINICAL ACTIVITY IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML). THE WEBINAR WILL TAKE PLACE ON THURSDAY, APRIL 30TH, 2026, AT 11:00 A.M.

CARDIFF ONCOLOGY TO HOST KEY OPINION LEADER DISCUSSION ON ONVANSERTIB'S PROMISING SINGLE-AGENT ACTIVITY

SAN DIEGO, APRIL 21, 2026 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL CANCER THERAPIES, TODAY ANNOUNCED IT WILL PRESENT UPDATED DATA FROM CRDF-004, A RANDOMIZED DOSE-FINDING PHASE 2 CLINICAL TRIAL EVALUATING ONVANSERTIB IN COMBINATION WITH STANDARD OF CARE (SOC) REGIMENS (FOLFIRI/BEVACIZUMAB (BEV) OR FOLFOX/BEV) IN PATIENTS WITH FIRST-LINE RAS-MUTATED METASTATIC COLORECTAL CANCER (MCRC). THE DATA WILL BE REVIEWED IN A RAPID ORAL PRESENTATION AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, TAKING PLACE MAY 29JUNE 2 IN CHICAGO.

CARDIFF ONCOLOGY TO PRESENT UPDATED PHASE 2 DATA OF ONVANSERTIB IN FIRST-LINE RAS-MUTATED MCRC IN A RAPID ORAL SESSION AT ASCO 2026

ONVANSERTIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN DEMONSTRATED ENHANCED ANTITUMOR ACTIVITY, INCLUDING TUMOR REGRESSION AND APOPTOSIS IN HER2-LOW BREAST CANCER MODELS, SUPPORTING ITS POTENTIAL FOR PATIENTS WITH LIMITED TREATMENT OPTIONS ONVANSERTIB IN COMBINATION WITH TRASTUZUMAB DERUXTECAN DEMONSTRATED ENHANCED ANTITUMOR ACTIVITY, INCLUDING TUMOR REGRESSION AND APOPTOSIS IN HER2-LOW BREAST CANCER MODELS, SUPPORTING ITS POTENTIAL FOR PATIENTS WITH LIMITED TREATMENT OPTIONS

CARDIFF ONCOLOGY PRESENTS PRECLINICAL DATA ON ITS PLK1 INHIBITOR ONVANSERTIB IN COMBINATION WITH A HER2-TARGETED ADC AT THE 2026 AACR ANNUAL MEETING

BOARD MEMBER AND INTERIM CEO MANI MOHINDRU, PHD, NAMED PRESIDENT AND CHIEF EXECUTIVE OFFICER APPOINTS INDUSTRY VETERANS JOSH MUNTNER AS CHIEF FINANCIAL OFFICER AND AJAY AGGARWAL, MD, MBA, AS CHIEF OPERATING OFFICER SAN DIEGO, APRIL 09, 2026 (GLOBE NEWSWIRE) -- CARDIFF ONCOLOGY, INC. (NASDAQ: CRDF), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEVERAGING PLK1 INHIBITION TO DEVELOP NOVEL THERAPIES ACROSS A RANGE OF CANCERS, TODAY ANNOUNCED THE APPOINTMENT OF MANI MOHINDRU, PHD, AS PRESIDENT AND CHIEF EXECUTIVE OFFICER (CEO), FOLLOWING HER TIME AS INTERIM CEO, AND THAT SHE WILL CONTINUE AS A MEMBER OF THE BOARD. THE COMPANY ALSO APPOINTED JOSH MUNTNER AS CHIEF FINANCIAL OFFICER AND AJAY AGGARWAL, MD, MBA, AS CHIEF OPERATING OFFICER, EFFECTIVE APRIL 6 AND APRIL 27, RESPECTIVELY.

Cardiff Oncology, Inc.

CRDF

Price

Financial Reports

No items found.

Press Releases

Cardiff Oncology, Inc.

CRDF.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CRDF